Chasing the Target: New Phenomena of Resistance to Novel Selective RET Inhibitors in Lung Cancer. Updated Evidence and Future Perspectives

SIMPLE SUMMARY: REarranged during Transfection (RET) is an emerging target for several types of cancer, including non-small cell lung cancer (NSCLC). The recent U.S. FDA approval of pralsetinib and selpercatinib raises issues regarding the emergence of secondary mutations and amplifications involved...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancers (Basel)
Main Authors: Fancelli, Sara, Caliman, Enrico, Mazzoni, Francesca, Brugia, Marco, Castiglione, Francesca, Voltolini, Luca, Pillozzi, Serena, Antonuzzo, Lorenzo
Formato: Artigo
Idioma:Inglês
Publicado em: MDPI 2021
Assuntos:
Review
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7961559/
https://ncbi.nlm.nih.gov/pubmed/33806299
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers13051091
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados